SCHEMBL9941261

SCHEMBL9941261

CNc1cc[nH]c1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.39
HCAR3 P49019 2/20 0.35
MAPT P10636 2/20 0.35
CNR2 P34972 1/20 0.35
KDM4E B2RXH2 3/20 0.33
PTPRC P08575 2/20 0.33
PTPN2 P17706 2/20 0.33
PTPN1 P18031 2/20 0.33
PTPRB P23467 2/20 0.33
PTPRE P23469 2/20 0.33
PTPN6 P29350 2/20 0.33
POLB P06746 1/20 0.33
ATM Q13315 1/20 0.33
ACHE P22303 1/20 0.33
PIN1 Q13526 1/20 0.33
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
ENPP2 Q13822 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KEAP1 Q14145 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18965199 0.83 PRKCI (0.39) KDM4CCNR2KDM4EPOLBATM
SCHEMBL27996373 0.82 CNR2 (0.37) KDM4CCNR2KDM4EPOLBATM
SCHEMBL4860925 0.76 KDM5A (0.43) CNR2KDM4EPTPRCPTPN2PTPN1
SCHEMBL27708741 0.74 KDM6B (0.48) KDM4CHCAR3MAPTKDM4EALDH1A1
SCHEMBL27689196 0.73 KDM6B (0.49) KDM4CHCAR3MAPTKDM4EALDH1A1
SCHEMBL257684 0.73
SCHEMBL3953211 0.72 MLYCD (0.34) KDM4CALDH1A1HPGDHSD17B10
SCHEMBL5519861 0.72 ALDH1A1 (0.51) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL69690 0.70 KEAP1 (0.47) MAPTKDM4EPTPRCPTPN2PTPN1
SCHEMBL27820699 0.69 NR4A2 (0.43) MAPTCNR2KDM4EPOLBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651413-B1 NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES PHARMAHUNGARY 2000 KFT (HU) 2017-11-22 EP disclosed
US-9487462-B2 Inhibitors of matrix metalloproteinases PHARMAHUNGARY 2000 KFT. (HU) 2016-11-08 US disclosed
US-20130303572-A1 NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES TARGETEX KFT. (HU) 2013-11-14 US disclosed
EP-2651413-A1 NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES Pharmahungary 2000 Kft. (HU) 2013-10-23 EP disclosed
WO-2012080762-A1 NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES PHARMAHUNGARY 2000 KFT. (HU) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303572-A1 NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES TIMP3, MMP3, MMP13 KDM4C 919/4885HCAR3 70/4885MAPT 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.